Posted by Michael Wonder on 04 Apr 2023
Long-waited drugs were approved, but patients must wait for insurance benefits
4 April 2023 - Braftovi (encorafenib) is a targeted agent used for VRAF V600E mutant metastatic colorectal cancer patients with previous treatment experiences in combination with cetuximab.
Ono Pharma Korea, which sells Braftovi, obtained its product approval from the Ministry of Food and Drug Safety in August 2021, immediately applied for its reimbursement to HIRA, and passed the cancer disease review committee in January the following year at a super speed.
